Reviews
Vol. 7 No. s8 (2013): The new oral anticoagulants in the Internal Medicine clinical practice
https://doi.org/10.4081/itjm.2013.s8.74

New oral anticoagulants: key messages for clinicians

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 9 December 2013
Published: 24 December 2013
1490
Views
1109
Downloads
new oral anticoagulants, internal medicine, management checklist.

Authors

Matteo Giorgi-Pierfranceschi
m.giorgi@ausl.pc.it
Emergency Department, Hospital of val d'Arda, Piacenza, Italy.
Chiara Cattabiani
Emergency Department, Hospital of val d'Arda, Piacenza, Italy.
Francesco Dentali
Internal Medicine Department, University of Insubria, Varese, Italy.
New oral anticoagulants are an effective and safe alternative to vitamin K antagonists in many fields of clinical practice. The use of the direct inhibitors of activated Factor II (dabigatran) and activated Factor X (apixaban and rivaroxaban), both in patients with non-valvular atrial fibrillation (NVAF) and those with acute venous thromboembolism (VTE), is of great interest for internal medicine physicians. This paper aims to give practical guidance on management (starting therapy, follow up and bleeding complications) of patients treated with dabigatran, rivaroxaban or apixaban for NVAF or acute VTE providing practical tables concerning the phases of therapy, management of complications, drug interaction and dose adjustment if renal impairment occurs.

Downloads

Download data is not yet available.

How to Cite



New oral anticoagulants: key messages for clinicians. (2013). Italian Journal of Medicine, 7(s8), 74-84. https://doi.org/10.4081/itjm.2013.s8.74

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.